Current concepts in Graves' disease

Therapeutic Advances in Endocrinology and Metabolism

Volumn 2, Issue 3, 2011, Pages 135-144

  Girgis, Christian M ^a   Champion, Bernard L ^b   Wall, Jack R ^b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

autoimmune thyroid disease; Graves' disease; hyperthyroidism; neomercazole; propylthiouracil; radioactive iodine; thionamides; thyroid eye disease; thyroidectomy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; COLESTYRAMINE; GLUCOCORTICOID; LIGAND; LITHIUM; PERTECHNETIC ACID TC 99M; PREDNISOLONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RITUXIMAB; SMALL MOLECULE LIGAND; THIAMAZOLE; THIONAMIDE; THYROID HORMONE; THYROTROPIN RECEPTOR; THYROXINE; UNCLASSIFIED DRUG;

ALGORITHM; ANTIBODY PRODUCTION; AUTOIMMUNITY; DEVELOPED COUNTRY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HEART FAILURE; HEPATITIS; HUMAN; HYPERTHYROIDISM; IMMUNE DEFICIENCY; LIVER FAILURE; LIVER TOXICITY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SORE THROAT; TACHYCARDIA; THYROID HYPERPLASIA; THYROIDECTOMY; THYROIDITIS; UNSPECIFIED SIDE EFFECT;

EID: 79960034296     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018811408488     Document Type: Review

References (49)

1. Abraham P. Avenell A. McGeoch S.C. Clark L.F. Bevan J.S. (2010) Antithyroid drug regimen for treating Graves’ hyperthyroidism (Cochrane review). Cochrane Database Syst Rev 1: CD003420–CD003420.
2. Abraham P. Avenell A. Park C.M. Watson W.A. Bevan J.S. (2005) A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153: 489–498.
3. Abraham-Nordling M. (2005) Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15: 1279–1286.
4. Abraham-Nordling M. Wallin G. Lundell G. Törring O. (2007) Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease. Eur J Endocrinol 156: 173–179.
5. Allannic H. Fauchet R. Orgiazzi B. Madec A.M. Genetet B. Lorcy Y. et al (1990) Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70: 675–679.
6. Amodio F. Di Martino S. Esposito S. Iorio S. Hierholzer J. Rea G. et al (2001) Role of flowmetric analysis and of color-Doppler ultrasonography with contrast media in the different phases and follow-up of Graves' disease. Radiol Med 102: 233–237.
7. Arab D.M. Malatjalian D.A. Rittmaster R.S. (1995) Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 80: 1083–1083.
8. Ayala C. Navarro E. Rodriguez J.R. Silva H. Venegas E. Astorga R. (1998) Conception after iodine-131 therapy for differentiated thyroid cancer. Thyroid 8: 1009–1011.
9. Bahn R.S. Burch H.S. Cooper D.S. Garber J.R. Greenlee C.M. Klein I.L. (2009) The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19: 673–673.
10. Bartalena L. Marcocci C. Bogazzi F. Manetti L. Tanda M.L. Dell'Unto E. et al (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73–78.
11. Baskin H.J. Cobin R.H. Duick D.S. Gharib H. Guttler R.B. Kaplan M.M. (2002) American Association of Clinical Endocrinologists medical guidelines for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endo Prac 8: 457–469.
12. Brent G.A. (2008) Graves' disease. N Engl J Med 358: 2544–2554.
13. Bonnema S.J. Bennedbaek F.N. Veje A. Marving J. Hegedüs L. (2006) Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab 91: 2946–2951.
14. Carroll G. Matfin G. (2010) Review: Endocrine and metabolic emergencies: thyroid storm. Ther Adv Endocrinol Metab 3: 139–145.
15. Cooper D.S. Rivkees S.A. (2009) Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94: 1881–1882.
16. Dobyns B.M. Sheline G.E. Workman J.B. Tompkins E.A. McConahey W.M. Becker D.V. (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 38: 976–978.
17. El Fassi D. Nielsen C.H. Bonnema S.J. Hasselbalch H.C. Hegeds L. (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92: 1769–1772.
18. El-Kaissi S. Frauman A.G. Wall J.R. (2004) Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 34: 482–491.
19. Franklyn J.A. Maisonneuve P. Sheppard M. Betteridge J. Boyle P. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353: 2111–2115.
20. Garcia-Mayor R.V.P.C. Luna-Cano R. Perez-Mendez L.F. Pérez Mendez L.F. Galofré J.C. Andrade A. (1992) Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrin Invest 15: 815–820.
21. Graham G.D. Burman K.D. (1986) Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 105: 900–905.
22. Greenlee C. Burmeister L.A. Butler R.S. Edinboro C.H. McIntyre Morrison S. Milas M. et al (2011) Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners. Thyroid 21: 151–160.
23. Jacobsen R. Lundsgaard C. Lorenzen J. Toubro S. Perrild H. Krog-Mikkelsen I. et al (2006) Subnormal energy expenditure: a putative casual factor in the weight gain induced by treatment of hyperthyroidism. Diabetes Obes Metab 8: 220–227.
24. Klein I. Ojamaa K. (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501–509.
25. Kubota S. Amino N. Matsumoto Y. Ikeda N. Morita S. Kudo T. et al (2008) Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis. Thyroid 18: 283–287.
26. Leslie W.D. Ward L. Salamon E.A. Ludwig S. Rowe R.C. Cowden E.A. (2003) A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 88: 978–983.
27. Luton D. Le Gac I. Vuillard E. Castanet M. Guibourdenche J. Noel M. et al (2005) Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 90: 6093–6098.
28. Maugendre D. Gatel A. Campion L. Massart C. Guilhem I. Lorcy Y. et al (1999) Antithyroid drugs and Graves' disease–prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 50: 127–132.
29. Manji N. Carr-Smith J.D. Boelaert K. Allahabadia A. Armitage M. Chatterjee V.K. et al (2006) Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91: 4873–4880.
30. Mariotti S. Caturegli P. Piccolo P. Barbesino G. Pinchera A. (1990) Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 71: 661–661.
31. Marx H. Amin P. Lazarus J.H. (2008) Hyperthyroidism and pregnancy. BMJ 336: 663–667.
32. Mercado M. Mendoza-Zubieta V. Bautista-Osorio R. Espinoza-de los Monteros (1996) Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 81: 3191–3193.
33. Nakamura H. Noh J.Y. Itoh K. Fukata S. Miyauchi A. Hamada N. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92: 2157–2162.
34. Neumann S. Eliseeva E. McCoy J.G. Napolitano G. Giuliani C. Monaco F. et al (2011) A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96: 548–554.
35. Neumann S. Huang W. Eliseeva E. Titus S. Thomas C.J. Gershengorn M.C. (2010) A small molecule inverse agonist for the human thyroid- stimulating hormone receptor. Endocrinology 151: 3454–3459.
36. Peters H. Fischer C. Bogner U. Reiners C. Schleusener H. (1996) Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 26: 59–63.
37. Reasner C.A. (1993) Autoimmune thyroid disease and type 1 diabetes. Diabetes Rev 1: 343–351.
38. Rotondi M. Cappelli C. Pirali B. Pirola I. Magri F. Fonte R. et al (1998) Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 139: 584–586.
39. Rosei E. Chiovato L. (2008) The effect of pregnancy on subsequent relapse from Graves' disease following a successful course of anti-thyroid drug therapy. J Clin Endocrinol Metab 93: 3985–3988.
40. Stenszky V. Kozma L. Balazs C. Rochlitz S. Bear J.C. Farid N.R. (1985) The genetics of Graves' disease: HLA and disease susceptibility. J Clin Endocrinol Metab 61: 735–740.
41. Toft A.D. (2001) Subclinical hyperthyroidism. N Engl J Med 345: 512–516.
42. Toft, A.D. and Beckett, G.J. (2003) Thyroid function tests and hypothyroidism. BMJ 326: 295–296.
43. Topliss D.J. Eastman C.J. (2004) Diagnosis and management of hyperthyroidism and hypothyroidism. Med J Australia 180: 186–193.
44. Traisk F. Tallstedt L. Abraham-Nordling M. Andersson T. Berg G. Calissendorff J. et al (2009) Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94: 3700–3707.
45. Van Dyk H.J. (1981) Orbital Graves' disease. A modification of the “NOSPECS” classification. Ophthalmology 88: 479–483.
46. Vitti P. Rago T. Mazzeo S. Brogioni S. Lampis M. De Liperi A. et al (1995) Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. Endocrinol Invest 18: 857–861.
47. Wartofsky L. Glinoer D. Solomon B. Nagataki S. Lagasse R. Nagayama Y. et al (1991) Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1: 129–135.
48. Woeber K.A. (2006) Triiodothyronine production in Graves' hyperthyroidism. Thyroid 16(7): 687–690.
49. Weetman A.P. (2003) Graves' disease 1835–2002. Horm Res 59(Suppl. 1): 114–118.